Not Yet RecruitingPhase 4ACTRN12625001211459

Immune Effects of Respiratory Syncytial Virus (RSV) Vaccination in Older Adults

Antibody and cellular responses to Arexvy or Abrysvo RSV Vaccination in Older Adults

Sponsor

Tasmanian Health Service

Enrollment

120 participants

Start Date

Jan 5, 2026

Study Type

Interventional

Conditions

Response to vaccination Depression Stress Anxiety

Summary

This is a prospective randomised trial investigating the immunological effects of two different RSV vaccines in older adults aged 60 years and above. Participants will be randomised to receive a single dose of either the Abrysvo or Arexvy RSV vaccine. Alongside standard antibody and cell mediated immunity assays, detailed exploratory systems biology assays (transcriptomics, epigenetics, lipidomics, metabolomics) and flow cytometry will be performed to investigate the broad immunomodulatory effects of RSV vaccination.

Eligibility

Sex: Both males and femalesMin Age: 60 Yearss

Inclusion Criteria4

Men and women aged 60 years and older with or without co-morbidities.
Ability to communicate in English.
Ability to communicate by mobile telephone and text messaging.
Written informed consent to participate in the trial.

Exclusion Criteria2

Known allergy or contraindication to Abrysvo or Arexvy RSV vaccination.
Unlikely to be available for the duration of the study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Randomised to receive a single 0.5mL dose intramuscularly of the Arexvy RSV vaccine. The vaccine will be administered by a research nurse who will not be directly supervised but will document the vacc